Canada
· Delayed Price · Currency is CAD BioSyent Statistics
Total Valuation
BioSyent has a market cap or net worth of CAD 131.00 million. The enterprise value is 114.59 million.
| Market Cap | 131.00M |
| Enterprise Value | 114.59M |
Important Dates
The next estimated earnings date is Friday, August 22, 2025.
| Earnings Date | Aug 22, 2025 |
| Ex-Dividend Date | May 30, 2025 |
Share Statistics
BioSyent has 11.25 million shares outstanding. The number of shares has decreased by -2.77% in one year.
| Current Share Class | 11.25M |
| Shares Outstanding | 11.25M |
| Shares Change (YoY) | -2.77% |
| Shares Change (QoQ) | -1.69% |
| Owned by Insiders (%) | 14.07% |
| Owned by Institutions (%) | 19.22% |
| Float | 8.58M |
Valuation Ratios
The trailing PE ratio is 17.44 and the forward PE ratio is 14.97.
| PE Ratio | 17.44 |
| Forward PE | 14.97 |
| PS Ratio | 3.42 |
| PB Ratio | 3.64 |
| P/TBV Ratio | 4.20 |
| P/FCF Ratio | 18.88 |
| P/OCF Ratio | 18.74 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 10.72, with an EV/FCF ratio of 16.51.
| EV / Earnings | 14.65 |
| EV / Sales | 2.99 |
| EV / EBITDA | 10.72 |
| EV / EBIT | 11.36 |
| EV / FCF | 16.51 |
Financial Position
The company has a current ratio of 4.90, with a Debt / Equity ratio of 0.03.
| Current Ratio | 4.90 |
| Quick Ratio | 3.90 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | 0.09 |
| Debt / FCF | 0.14 |
| Interest Coverage | 177.97 |
Financial Efficiency
Return on equity (ROE) is 22.17% and return on invested capital (ROIC) is 17.33%.
| Return on Equity (ROE) | 22.17% |
| Return on Assets (ROA) | 15.23% |
| Return on Invested Capital (ROIC) | 17.33% |
| Return on Capital Employed (ROCE) | 27.32% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.93 |
| Inventory Turnover | 1.50 |
Taxes
In the past 12 months, BioSyent has paid 2.71 million in taxes.
| Income Tax | 2.71M |
| Effective Tax Rate | 25.74% |
Stock Price Statistics
The stock price has increased by +16.40% in the last 52 weeks. The beta is 0.44, so BioSyent's price volatility has been lower than the market average.
| Beta (5Y) | 0.44 |
| 52-Week Price Change | +16.40% |
| 50-Day Moving Average | 11.33 |
| 200-Day Moving Average | 11.14 |
| Relative Strength Index (RSI) | 50.41 |
| Average Volume (20 Days) | 2,284 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, BioSyent had revenue of CAD 38.28 million and earned 7.82 million in profits. Earnings per share was 0.67.
| Revenue | 38.28M |
| Gross Profit | 30.05M |
| Operating Income | 10.08M |
| Pretax Income | 10.53M |
| Net Income | 7.82M |
| EBITDA | 10.56M |
| EBIT | 10.08M |
| Earnings Per Share (EPS) | 0.67 |
Balance Sheet
The company has 17.40 million in cash and 990,218 in debt, giving a net cash position of 16.41 million or 1.46 per share.
| Cash & Cash Equivalents | 17.40M |
| Total Debt | 990,218 |
| Net Cash | 16.41M |
| Net Cash Per Share | 1.46 |
| Equity (Book Value) | 36.01M |
| Book Value Per Share | 3.20 |
| Working Capital | 22.80M |
Cash Flow
In the last 12 months, operating cash flow was 6.99 million and capital expenditures -49,457, giving a free cash flow of 6.94 million.
| Operating Cash Flow | 6.99M |
| Capital Expenditures | -49,457 |
| Free Cash Flow | 6.94M |
| FCF Per Share | 0.62 |
Margins
Gross margin is 78.51%, with operating and profit margins of 26.35% and 20.43%.
| Gross Margin | 78.51% |
| Operating Margin | 26.35% |
| Pretax Margin | 27.52% |
| Profit Margin | 20.43% |
| EBITDA Margin | 27.59% |
| EBIT Margin | 26.35% |
| FCF Margin | 18.13% |
Dividends & Yields
This stock pays an annual dividend of 0.19, which amounts to a dividend yield of 1.63%.
| Dividend Per Share | 0.19 |
| Dividend Yield | 1.63% |
| Dividend Growth (YoY) | 11.76% |
| Years of Dividend Growth | 3 |
| Payout Ratio | 27.09% |
| Buyback Yield | 2.77% |
| Shareholder Yield | 4.40% |
| Earnings Yield | 5.97% |
| FCF Yield | 5.30% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
BioSyent has an Altman Z-Score of 13.92 and a Piotroski F-Score of 4.
| Altman Z-Score | 13.92 |
| Piotroski F-Score | 4 |